FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

Source: Nasdaq GlobeNewswire / 09 Jun 2023 18:45:00   America/New_York